Company profile: Molecular Devices
1.1 - Company Overview
Company description
- Provider of analytical solutions for cell and protein biology, enabling customers to unravel complex biological systems. Offerings include AI-driven automated cell culture (CellXpress.ai), high-content confocal imaging (ImageXpress), SpectraMax microplate readers, SoftMax Pro software for data analysis, GxP compliance solutions, and an Organoid Innovation Center for 3D biological models.
Products and services
- ImageXpress High-Content Confocal Imaging System: Delivers AI-driven technology enabling efficient, detailed confocal imaging for high-content cellular analysis, streamlining complex biological studies
- SpectraMax Microplate Readers: Produces microplate readers for a variety of assays, supporting research in protein and cell biology with reliable performance and streamlined laboratory workflows, multi-assay
- CellXpress.ai Automated Cell Culture System: Automates cell culture processes with machine learning–assisted monitoring, improving workflow efficiency and assay reliability across cell biology experiments
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Molecular Devices
BioGene
HQ: United Kingdom
Website
- Description: Provider of a solution-based portfolio of products, services, and support covering key application areas of molecular biology, dedicated to developing and implementing molecular and engineering technologies to improve access to diagnostic testing and enhance global health outcomes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioGene company profile →
Nebion
HQ: Switzerland
Website
- Description: Provider of precise curation and advanced analytics of public and private studies to enable the future of genomic research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nebion company profile →
Tessera Therapeutics
HQ: United States
Website
- Description: Provider of Gene Writing technology for permanent therapeutic alterations to the human genome, offering RNA Gene Writers to change base pairs, make small insertions, deletions or replacements, and integrate entire genes without double stranded breaks; DNA Gene Writers to durably write new DNA sequences with potential one-time cures; and a proprietary lipid nanoparticle delivery system for safe, effective nucleic acid delivery beyond the liver.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tessera Therapeutics company profile →
Emulate
HQ: United States
Website
- Description: Provider of advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emulate company profile →
Ncardia
HQ: The Netherlands
Website
- Description: Provider of iPSC-based drug discovery platforms and predictive human cellular assay systems to expedite drug discovery from hit identification to lead optimization. Offers Ncyte Smooth Muscle Cells, Astrocytes, Endothelial Cells, Neural Mix, and vCardiomyocytes for in vitro modeling, safety and efficacy testing, cardiovascular and neural screening, pharmacology, toxicity, electrophysiology, and disease modeling.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ncardia company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Molecular Devices
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Molecular Devices
2.2 - Growth funds investing in similar companies to Molecular Devices
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Molecular Devices
4.2 - Public trading comparable groups for Molecular Devices
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →